General information

Announcements(21)

Program

Sessions

Search presentations

Download PDF for print

Timetable

Tue. Nov 26, 2024

Wed. Nov 27, 2024

Thu. Nov 28, 2024

Fri. Nov 29, 2024

web_header_st_en.png

Announcements

Profile management

Bookmark

Program Type

Live Streaming Available

Late-breaking Abstract

ポスターカテゴリ

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Rational design of superior CAR T cells through Ingenuity Pathway Analysis

QIAGEN Ingenuity Pathway Analysis (IPA) supports the interpretation of your omics data by utilizing a high-quality knowledge base and a large amount of omics data from past research. This time, we will focus on the very hot field of chimeric antigen receptor (CAR) T cell therapy. CAR-T cell therapy is a promising treatment that aims to cure recurrent and refractory cancers, but the disease group in which it can provide sustained efficacy is still limited. Currently, research is being conducted to change the function of CAR-T cells. In order to make rational modifications to T cells, it is important to narrow down the process of finding key molecules related to functional decline such as terminal differentiation and exhaustion of T cells from comprehensive gene expression data such as RNA sequencing. By using IPA to search for upstream regulatory molecules that cause the comprehensive changes in RNA abundance, it may be possible to apply it to the rational improvement and development of CAR-T cells. In this presentation, we will introduce specific examples of CAR-T cell modifications that the presenter's group is promoting based on IPA interpretation.<br>

The 47th Annual Meeting of the Molecular Biology Society of Japan

Presentation Information

[2BT-03-02]Rational design of superior CAR T cells through Ingenuity Pathway Analysis

Comment